A clinical plan whose key readout lands after the money runs out is not a plan. Emerging biotechs align milestones with runway by defining the value-inflection readout precisely, modeling the timeline with realistic and downside scenarios, mapping cash burn to the activities that drive it, keeping a meaningful buffer beyond the readout and deciding in advance which levers they would pull if the math doesn't work.
Why do clinical plans and runways drift apart?
Timelines are built optimistically. Costs are back-loaded, with large site and data management expenses arriving later in the study. Financing assumptions change. And many plans treat the last patient's last visit as if it were the readout, forgetting the months it takes to clean data, lock the database, analyze results and understand what they mean.
What is the right milestone?
The one investors and partners will value: the readout that changes the company's options. Define it precisely. Which data, from how many participants, analyzed how, answering which question? A vague milestone invites a vague plan.
How should you model the timeline?
Build at least two scenarios: expected and downside. Model site activation and enrollment as curves, not straight lines. Include the period from last patient visit to topline results, and any regulatory interactions that sit on the critical path. Be honest about which assumptions are evidence and which are hope.
How should cash and timeline connect?
Map monthly burn to the activities that drive it: CRO fees and payment schedules, pass-through costs, drug supply, regulatory work and internal headcount. Add contingency explicitly. Then find the date when cash runs out under the downside scenario. That date, not the expected one, is the number your board should see.
How much buffer is needed after a readout?
Enough to analyze, interpret, communicate and act on the results, whether that means raising capital, partnering or starting the next study. A company that reaches its readout with only weeks of cash left negotiates from weakness, however good the data are.
What levers exist if the math doesn't work?
Narrow the scope: fewer arms, a smaller sample or a more focused population.
Add an interim analysis that can provide an earlier signal.
Stage the program with clear go or no-go gates.
Pursue non-dilutive funding or a development partner.
Revisit site and country strategy for cost and speed.
Raise earlier, before the gap becomes visible to everyone.
Each lever has trade-offs, and the time to weigh them is before the study starts, not when the runway is short.
How often should you revisit the plan?
Monthly, alongside the clinical trial accrual and forecast. Enrollment, site activation and spending trends will tell you early whether the expected or downside scenario is unfolding. Boards appreciate seeing that movement long before it becomes a crisis.
Keep reading: What Investors Look For in Your Clinical Operations
